3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Melanoma
5
Triple Negative Breast Neoplasms
4
Small Cell Lung Carcinoma
4
Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma, Hepatocellular
4
Breast Neoplasms
4
Urinary Bladder Neoplasms
3
Stomach Neoplasms
2
Mesothelioma, Malignant
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Merkel Cell
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Small Cell Lung Cancer Recurrent
1
Safety Issues
1
Recurrent Liver Cancer After Liver Transplantation
1
Recurrence
1
Radiation Pneumonitis
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasm Metastasis
1
Lymphoma
1
Lung Neoplasms
1
Locally Advanced or Metastatic Solid Tumors
1
Liver Neoplasms
1
Kidney Neoplasms
1
Hodgkin Disease
1
Interventions
Docetaxel
5
Pemetrexed
4
Capecitabine
4
pembrolizumab
3
Oxaliplatin
3
icotinib
2
Radiation
2
Paclitaxel
2
Gemcitabine
2
Gefitinib
2
Fluorouracil
2
Drug Therapy
2
Chemoradiotherapy
2
Carboplatin
2
sintilimab
1
rucaparib
1
regorafenib
1
olaparib
1
lenvatinib
1
iron isomaltoside 1000
1
ipatasertib
1
iopromide
1
gluconic acid
1
elemene
1
capecitabine-irinotecan combination
1
aumolertinib
1
atezolizumab
1
anlotinib
1
aflutinib
1
XELOX
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Adenocarcinoma
×
atezolizumab
×
Clear all
NCT04739202
2021-03-29
IMMUNOGAST
Hospices Civils de Lyon
Phase 2
Unknown
60 enrolled